Every few years a molecule comes along that resets the conversation. Semaglutide did it. Tirzepatide did it again. And now there is retatrutide, a triple-hormone agonist that hits not one or two metabolic receptors but three, and that has posted the largest average weight loss ever recorded in a Phase 3 obesity trial. If you have been following the science, you already know the numbers are extraordinary. The good news is that you do not have to wait years to access this therapy.
At iRevive, retatrutide is part of our medical weight management program right now. We provide it through licensed compounding pharmacy partnerships, paired with the comprehensive labs, clinician oversight, and ongoing monitoring that make a therapy this powerful both safe and genuinely effective. What follows is a clinician’s read on what makes retatrutide so remarkable, what the data actually shows, and how we use it to help patients achieve high-quality, durable results.
What is retatrutide?
Retatrutide (research designation LY3437943) is a once-weekly injectable triple agonist, a single molecule engineered to activate three different hormone receptors at once. That is why it is called a triple agonist, and that triple action is the reason it has produced weight-loss numbers unlike anything we have seen before. iRevive offers retatrutide today through licensed compounding pharmacy partnerships, with full clinical supervision.
The medications most people know, semaglutide and tirzepatide, work on one or two of the body’s incretin pathways. Retatrutide adds a third. That third target is the headline. We will get into the mechanism in a moment, but the short version is that retatrutide does not just turn down appetite. It also appears to turn up how much energy the body burns. That combination is what has produced the eye-catching results.
It is worth understanding how retatrutide differs from the medications already on the market, and we have written a separate, detailed breakdown of the incretin classes in our GLP-1 vs. GLP-2 vs. GLP-3 Complete Guide. This article goes deep on retatrutide specifically.
How does retatrutide work?
Retatrutide agonizes three receptors: GIP, GLP-1, and glucagon. The first two reduce appetite and slow gastric emptying, which is the familiar GLP-1 mechanism. The glucagon component is the differentiator, because it is thought to increase energy expenditure and fat metabolism rather than only suppressing intake.
Here is why that is so exciting. For years, glucagon was viewed mostly as the hormone that raises blood sugar, the opposite of insulin. But at the doses and in the molecular design used in retatrutide, glucagon agonism appears to push the body toward burning stored fat and increasing metabolic rate, while the GLP-1 and GIP activity keeps blood sugar in check and appetite down. The three signals are balanced against each other in a single, elegant molecule.
Think of the existing GLP-1 receptor agonists as working primarily on the “calories in” side of the equation. They make you less hungry, you eat less, you lose weight. Retatrutide is designed to work on both sides at once. It quiets appetite and, through the glucagon arm, nudges the “calories out” side upward. That dual action is the mechanistic story behind the triple-agonist approach, and it is the reason researchers expected, and have now confirmed, larger reductions in body weight.
How much weight do people lose on retatrutide?
In the studies completed so far, retatrutide has produced some of the largest reductions in body weight ever reported for a medication. The Phase 2 trial showed up to roughly 24% average weight loss at 48 weeks, and the pivotal Phase 3 trial reported about 28% average at the highest dose, with a subset reaching just above 30% in an extension. These are the strongest weight-reduction results recorded in trials to date.
Let me walk through the actual evidence, because the numbers deserve context.
The Phase 2 trial was published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues. It enrolled 338 adults who had obesity or were overweight and did not have type 2 diabetes, and followed them for 48 weeks. At the 12 mg study dose, participants lost a mean of about 24.2% of their body weight. For a Phase 2 study, that was a striking signal, enough to make the entire obesity-medicine world sit up.
Then came the Phase 3 TRIUMPH program, and the results reported in 2026 confirmed the early promise. TRIUMPH-1, the large pivotal obesity trial, enrolled 2,339 patients. At 80 weeks, the average weight reductions were roughly 19% on the 4 mg study dose, about 26% on 9 mg, and about 28.3% on 12 mg. Nearly half of the patients on the 12 mg dose, around 45%, lost at least 30% of their body weight. A 104-week extension in patients with higher starting BMI reached an average of about 30.3%, which translated to roughly 85 pounds. A separate trial, TRIUMPH-4, ran 68 weeks at the 12 mg study dose and reported about 28.7%.
The benefits went well beyond the scale. Reported findings included an LDL cholesterol reduction of roughly 20%, a meaningful reduction in osteoarthritis-related pain, and, in the subgroup who started with prediabetes, a high rate of returning to normal blood sugar. In other words, retatrutide is not only moving the number on the scale, it is improving the metabolic markers that matter most for long-term health.
These are remarkable figures. They come from controlled clinical trials in selected populations with intensive support and monitoring, and individual results always vary. That is precisely why the way a therapy is delivered matters so much, and it is where iRevive’s model makes the difference.
How does retatrutide compare to tirzepatide and semaglutide?
In comparisons across trials, retatrutide has produced roughly 5 percentage points more average weight loss than the highest tirzepatide dose in similar patient populations. The reason is the third receptor, the glucagon arm, which tirzepatide and semaglutide do not have. This is a cross-trial comparison rather than a head-to-head study, so the figures are best read as orientation, but the pattern is consistent and compelling.
Here is how the three sit side by side.
| Drug | Receptor targets | Approx. trial weight loss | Notes |
| Retatrutide (LY3437943) | GIP + GLP-1 + glucagon (triple agonist) | ~24% at 48 wks (Phase 2); ~28% at 80 wks, up to ~30% in extension (Phase 3) | Glucagon arm raises energy expenditure. Largest Phase 3 obesity weight loss reported to date. Offered now through iRevive via licensed compounding pharmacies. |
| Tirzepatide | GIP + GLP-1 (dual agonist) | ~21% to 23% at highest dose | Strong, established track record. A proven option under clinician supervision. |
| Semaglutide | GLP-1 only (single agonist) | ~15% to 17% | The most studied of the three, with a large real-world and cardiovascular evidence base. |
A note on this table. The weight-loss figures come from separate trials with different protocols, durations, patient populations, and time points, so they are useful for orientation rather than precise head-to-head ranking. What the data consistently shows is that adding the third receptor delivers a meaningful step up in average results. Your clinician will help you choose the option that fits your physiology and goals.
Is retatrutide right for me?
Retatrutide may be an excellent fit if you are carrying weight that is affecting your health and you want one of the most powerful tools medical science has produced, delivered the right way. The best first step is a proper evaluation so that the decision is grounded in your physiology rather than a one-size-fits-all template. That is exactly how every iRevive protocol begins.
The fully branded retatrutide product is completing FDA review, and iRevive provides retatrutide today through licensed compounding pharmacy partnerships. That means you can access this therapy now, responsibly, with a clinician guiding every step, including baseline labs and ongoing monitoring. You get the benefit of a breakthrough medication and the safeguards of real medical oversight at the same time.
Like the broader GLP-1 class, retatrutide can cause gastrointestinal effects such as nausea or diarrhea, typically most noticeable when starting or moving up in dose. These are very manageable when a clinician is escalating your dose deliberately and watching your response, which is precisely the kind of supervision iRevive builds in. Your provider will review your history, your labs, and your goals to determine whether retatrutide is the right choice for you.
How does iRevive use retatrutide?
At iRevive, retatrutide is a centerpiece option within our medical weight management program, and we deliver it the way a therapy this powerful deserves to be delivered. We practice concierge functional medicine as a Florida-based telehealth model, which means direct access to your clinician without the friction of a traditional practice. Membership is $99 per month.
Before we recommend any protocol, we start with comprehensive biomarker analysis so that decisions are grounded in your actual physiology. From there, our medical weight management approach pairs retatrutide with the ongoing monitoring and lifestyle work that make results both safe and durable. We are deliberate about protecting lean muscle, because more weight loss is only better when it is the right kind of weight loss. That means adequate protein intake, resistance training guidance, and follow-up labs, so that what comes off is fat and what stays is the muscle that keeps you strong and metabolically healthy.
This is the iRevive difference. A breakthrough molecule is only as good as the care around it, and our model is built to turn retatrutide’s remarkable potential into a high-quality, sustainable result you can feel proud of. If you are ready to explore medical weight management, we would love to talk with you.
Frequently Asked Questions
Can I get retatrutide through iRevive?
Yes. iRevive offers retatrutide today through licensed compounding pharmacy partnerships, with comprehensive baseline labs, clinician oversight, and ongoing monitoring. Your provider will review your history and goals to confirm it is the right fit before starting. The best first step is to book a medical weight management consultation.
How does retatrutide compare to tirzepatide?
In separate trials, retatrutide has shown larger average weight loss, roughly 5 percentage points more than the highest tirzepatide dose, thanks to its third receptor target. These were not head-to-head studies, so the figures are best read as orientation. Both can be excellent options, and your clinician will help you choose based on your physiology and goals.
How much weight can people lose on retatrutide?
In Phase 3 TRIUMPH-1, patients on the highest study dose lost an average of about 28% of body weight at 80 weeks, with an extension in higher-BMI patients reaching about 30%. Phase 2 showed about 24% at 48 weeks. These are controlled-trial averages, and individual results vary with each person’s physiology and plan.
Does iRevive monitor patients on retatrutide?
Absolutely. Comprehensive monitoring is core to how we work. We start with baseline biomarker analysis, escalate deliberately, and track your response with follow-up labs and clinician check-ins. We also build in muscle-preservation guidance so your results reflect quality body composition, not just a smaller number on the scale.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual results from any medication vary, and no outcome is guaranteed. Retatrutide is provided through licensed compounding pharmacy partnerships under clinician supervision; the fully branded product is completing FDA review. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment. iRevive Integrative & Functional Medicine provides care via a concierge telehealth model across Florida.
